



14 August, 2025

My Dear Shareholders,

As Chairman of the Company, I am pleased to share with you the performance of Wockhardt Limited for the first quarter of FY26. It gives me immense pleasure to present the performance of our Company which is committed to working on achieving medical breakthroughs and in creating new standards – in science, in ethics and in long-term public health commitment.

### Our Performance:

 **INR 738 Cr.**  
Revenue


 **INR 101 Cr.**  
EBITDA

Revenue for Q1FY26 is ₹738 Crore compared to ₹747 Crore in the previous year. EBITDA for Q1FY26 was ₹101 Crore, reflecting a QoQ growth of 1% compared to ₹100 Crore in the previous year.

The Company's business approach is to continue the growth momentum with a focus on profitability while balancing investments in an innovative portfolio comprising Novel Antibiotics and Diabetes Biosimilars to build an organization across various aspects of regulatory, clinical, medical and commercial excellence for pre-launch and launch activities in India and developed markets.

### Novel Antibiotic Update:

**ZAYNICH<sup>®</sup> (Zidebactam/Cefepime, WCK 5222) Filed for approval in India and pre-NDA submission meetings completed with US FDA**



Zaynich is manufactured and supplied from US FDA approved third party manufacturing sites in Europe for USA and developed markets.

The following two trials have been completed with remarkable clinical efficacy;

1. Global, pivotal, registration-enabling, Phase III study in hospitalized complicated urinary tract infection (cUTI) patients and
2. Trial in patients with meropenem-resistant infections in India

Two pre-NDA meetings with US FDA have been successfully completed and the filing of the New Drug Application (NDA) dossier is targeted in September 2025. In India, the NDA has already been submitted on March 31, 2025.


**Leading U.K. Medical Journal publishes a Complex Case of Severe Pan-drug Resistant Infection in U.S. Liver Transplant Patient Successfully Treated with Zaynich®**

Zaynich® continues to demonstrate its life-saving attributes under compassionate use. One such case was recently published by a top-notch British medical journal- Journal of Antimicrobial Chemotherapy – AMR, describes ability of Zaynich® in rescuing a US patient.



The publications have been jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins. Likewise, in another publication in Journal of Global Antimicrobial Resistance, a case series comprising of 5 Bone and Joint Infections patients successfully treated with Zaynich® has been published by clinicians from Christian Medical College, Vellore. These patients were treated with Zaynich® for 4-6 weeks.

**MIQNAF® NAFITHROMYCIN, approved and launched on May 27 2025, in India**



Following the launch of Miqnaf®, initial response from clinicians across India has been very encouraging. Within a few weeks of its launch the prescriptions have reached >1000 and several doctors are now repetitively prescribing, realizing the clinical value of the antibiotic.

**97%**  
 Success Rate in  
 Community Acquired  
 Pneumonia  
**Ultra Short**  
**3-Day**  
 Treatment

**EMROK/ EMROK O:**

A landmark publication in a reputed UK medical journal – Journal of Antimicrobial Resistance – AMR has published a nearly untreatable case of bone and joint infections caused by one of the toughest pathogens – Burkholderia pseudomallei. Initial treatment with two most commonly used antibiotics, trimethoprim/sulfamethoxazole and ceftazidime failed as the patient turned allergic to both. With no treatment option, Emrok emerged as the salvage therapy for this patient, achieving clinical improvement without relapse with > 8 months of therapy. Notably, even after more than 6 months after completing the therapy, the patient remained infection-free. This first reported use of Emrok in melioidosis underscores its potential as a valuable drug option in such complex infections.

**EMROK**  
**EMROK-O**

**>100,000** PATIENTS TREATED

**ERTAPENEM-ZIDEBACTAM (WCK 6777):**

A Phase 2 study protocol is under development comparing once-a-day WCK 6777 with a leading novel three-times-a-day antibiotic for the treatment of resistant infection. This study would help identify the clinical dose for Phase 3 study. US FDA has recently granted a Fast-track designation to WCK 6777 for two indications – cUTI and cIAI.




**FOVISCU (WCK 4282):**

Phase 3 study of WCK 4282 is slated to be completed in FY 25-26. This study compared WCK 4282 with leading hospital antibiotic meropenem. The results of this study would form the basis for filing NDA. The clinical data of Phase 3 study would position WCK 4282 as an effective drug for the treatment of highly prevalent ESBL infections for which current treatment options - piperacillin/tazobactam and cefoperazone/sulbactam have been compromised due to rising resistance.

**Strategic Realignment of US Operations to Focus on Innovative Portfolio**

As part of our ongoing strategic transformation, Wockhardt has completed a planned exit from its US generics business to eliminate recurring losses and enable sharper focus on innovation-led growth. This move aligns with our global priorities and unlocks capital and management bandwidth to accelerate progress in our differentiated antibiotic discovery and insulin biologics portfolios—key pillars of our future-ready business model.

**Region-wise Business Highlights:**



**India Business** stood at ₹178 crore in Q1FY26 with a growth of 8% compared to the previous year.

**UK Business** stood at ₹312 crore in Q1FY26 with a growth of 13% compared to the previous year.

**Irish Business** stood at ₹50 crore in Q1FY26 with a growth of 11% compared to the previous year.

### New Products Launch:

- ◆ 1 Filing and 4 Launches in Wockhardt UK and Pinewood
- ◆ Biosimilars & NCE - 6 Filings & 6 Approvals
- ◆ EMROK/ EMROK O - Registration has been filed in 9 countries of ROW and other markets
- ◆ Approval received for EMROK O for Uganda

### Intellectual Property Update:

- ◆ 5 patents were filed during the quarter ended 30<sup>th</sup> June 2025 and the cumulative filings till date are 3278.
- ◆ The company was granted 5 patents during the quarter and now holds 853 patents.

<b>PATENTS</b>
Filings till Date : <b>3278</b>
Patents held : <b>853</b>

### Way Forward:

We are thrilled to share that Wockhardt continues to make ground-breaking strides in drug discovery, positioning us as a leader among Indian pharmaceutical companies in tackling global healthcare challenges. Our strategic focus on novel antibiotics and diabetes biosimilars is driving impactful growth and innovation. Here's our roadmap for the future:

**Accelerating Novel Antibiotics Commercialization:** Our flagship antibiotic, Zaynich<sup>®</sup> (WCK 5222), has achieved remarkable milestones, including a 20% higher composite cure rate compared to meropenem in a global Phase 3 study for complicated urinary tract infections (cUTI) and over 90% clinical efficacy in treating carbapenem-resistant infections in India. With >70 patients, including 3 in the US & 1 in France, successfully treated under compassionate use, Zaynich<sup>®</sup> is proving its life-saving potential. Following the NDA submission in India and successful pre-NDA meetings with the US FDA, we are on track to file for US approval in September 2025. Additionally, Miqnaf<sup>®</sup> (Nafithromycin), launched in India in May 2025, has garnered over 1,000 prescriptions and a 97% success rate in treating Community-Acquired Bacterial Pneumonia (CABP) with a three-day ultra-short course. It's Breakthrough Medicine designation in Saudi Arabia signals imminent approvals, further expanding our global footprint. The ongoing Phase 3 study for Foviscu (WCK 4282) and Phase 2 protocol development for Ertapenem-Zidebactam (WCK 6777), with Fast-track designation for cUTI and cIAI, underscore our robust pipeline, supported by six US FDA QIDP designations to address the global antimicrobial resistance (AMR) crisis.


**Scaling Diabetes Biosimilars:** Our diabetes Biosimilars portfolio, including Human Insulin and Insulin Glargine, continues to experience strong demand in India and emerging markets, with 6 filings and 6 approvals in Q1FY26. We are investing in upgrading and expanding our biosimilar manufacturing facilities to support this growth and facilitate entry into new markets, reinforcing Wockhardt's leadership in diabetes care.

**Expanding Global Reach and Innovation:** Our strategic exit from the US generics business has freed resources to focus on our innovative portfolio, enabling accelerated progress in novel antibiotics and Biosimilars. With regional growth of 8% in India, 13% in the UK, and 11% in Ireland, alongside new product launches and registrations, we are strengthening our global presence.

**Commitment to Excellence:** We remain dedicated to addressing unmet medical needs through innovation, regulatory excellence, and strategic commercialization. By advancing Zaynich<sup>®</sup>, Miqnaf<sup>®</sup>, and our Biosimilars portfolio, we aim to deliver transformative healthcare solutions globally.

We express our gratitude to each of you for your ongoing support and confidence in Wockhardt. Our commitment remains steadfast as we concentrate on fortifying the business at Wockhardt, and we sincerely seek your unwavering support.

Warm Regards,



Dr. Habil Khorakiwala  
Founder Chairman

*For further clarification, write to: Investor Service Cell, Wockhardt Limited, Wockhardt Towers, Bandra-Kurla Complex, Bandra East, Mumbai 400 051 or Email: [investorrelations@wockhardt.com](mailto:investorrelations@wockhardt.com)*